Breakfast of champions: MIT hosts top young scientists
At an MIT-led event at AJAS/AAAS, researchers connect with MIT faculty, Nobel laureates, and industry leaders to share their work, gain mentorship, and explore future careers in science.
At an MIT-led event at AJAS/AAAS, researchers connect with MIT faculty, Nobel laureates, and industry leaders to share their work, gain mentorship, and explore future careers in science.
Stefani Spranger is working to discover why some cancers don’t respond to immunotherapy, in hopes of making them more vulnerable to it.
Markey Freudenburg-Puricelli, Abigail Schipper ’24, and Rachel Zhang ’21 will pursue graduate studies at Cambridge University in the U.K.
FragFold, developed by MIT Biology researchers, is a computational method with potential for impact on biological research and therapeutic applications.
Colleagues remember the longtime MIT professor as a supportive, energetic collaborator who seemed to know everyone at the Institute.
They identified proteins that influence splicing of about half of all human introns, allowing for more complex types of gene regulation.
Whitehead Institute and CSAIL researchers created a machine-learning model to predict and generate protein localization, with implications for understanding and remedying disease.
In the United States and abroad, Matthew Dolan ’81 has served as a leader in immunology and virology.
Studying the pathogen R. parkeri, researchers discovered the first evidence of extensive and stable interkingdom contacts between a pathogen and a eukaryotic organelle.
At a symposium of the Simons Center for the Social Brain, six speakers described a diversity of recently launched studies aimed at improving understanding of the autistic brain.
Ten objects on display in the Koch Institute Public Galleries offer uncommon insights into the people and progress of MIT's cancer research community.
Laureates participated in various Nobel Week events, including lectures, a concert, a banquet, and the Nobel ceremony on Dec. 10.
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
New research reveals what it takes for a protein that is best known for protecting cells against death to take on the opposite role.